Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-09
2007-01-09
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252110, C514S252130, C514S252140, C514S253050, C514S253060, C514S253090, C514S254010, C514S254020, C514S254030, C514S254050, C514S254100, C514S254100, C544S182000, C544S238000, C544S297000, C544S322000, C544S360000, C544S363000, C544S365000, C544S366000, C544S367000, C544S369000, C544S370000, C544S371000, C544S372000, C544S379000
Reexamination Certificate
active
10788859
ABSTRACT:
Certain novel N-acylated piperazine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
REFERENCES:
patent: 5576290 (1996-11-01), Hadley
patent: 6051555 (2000-04-01), Hadley
patent: 6329403 (2001-12-01), Odaka et al.
patent: 2003/0153556 (2003-08-01), Levy et al.
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/58891 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/059095 (2002-08-01), None
patent: WO 02/059107 (2002-08-01), None
patent: WO 02/059108 (2002-08-01), None
patent: WO 02/059117 (2002-08-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 02/070511 (2002-09-01), None
patent: WO 03/007949 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/066597 (2003-08-01), None
patent: WO 03/093234 (2003-11-01), None
patent: WO 03/094918 (2003-11-01), None
patent: WO 2005/040109 (2005-05-01), None
Huszar et al., Cell, vol. 88 (1997), pp. 131-141, “Targeted disruption of the melanocortin-4 receptor results in obesity in mice”.
Dinsmore et al., Brit. Med. J., vol. 318 (1999), pp. 387-390, “ABC of sexual health—erectile dysfunction”.
Kask et al., Biochem. & Biophys. Res. Comm., vol. 245 (1998), pp. 90-93, “Selective antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats”.
Chen et al., Cell, vol. 91 (1997), pp. 789-798, “Exocrine gland dysfunction in MC5-R-deficient mice . . . ”.
Gingell et al., Exp. Opin. Ther. Patents, vol. 9 (1999), pp. 1689-1696, “Emerging pharmacological therapies for erectile dysfunction”.
Moreland et al., Life Sciences, vol. 62, No. 20 (1998), pp. PL-309-318, “Sildenafil, A novel inhibitor of phosphodiesterase Type 5 in human corpus cavernosum smooth muscle cells”.
Giraudo et al., Brain Res. vol. 809 (1998), pp. 302-306, “Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands”.
Graul, Drugs News & Perspectives, vol. 9 (1996), pp. 572-575, “Latest findings on the diagnosis and treatment of erectile dysfunction”.
Kopelman, Nature, vol. 404 (2000), pp. 635-643, “Obesity as a medical problem”.
Hill et al., Science, vol. 280 (1998), pp. 1371-1374, “Environmental contributions to the obesity epidemic”.
Davidson et al., JAMA, vol. 281 (1999), pp. 235-242, “Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat”.
Guy Grand et al., Lancet, vol. 2 (1989), pp. 1142-1145, “Therapeutics: International trial of long-term dexfenfluramine in obesity”.
Bray et al., Obesity Research, vol. 7 (1999), pp. 189-198, “Sibutramine produces dose-related weight loss”.
Yoram et al., Current Opinion in Urology, vol. 7 (1997), pp. 349-353, “Oral pharmacotherapy in erectile dysfunction”.
Heaton et al., Int'l J. of Impotence Res., vol. 9 (1997), pp. 115-121, “A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative”.
Dorr et al., Life Sciences, vol. 58, No. 20 (1996), pp. 1777-1784, “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study”.
Wessells et al., Urology, vol. 56 (2000), pp. 641-646, “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction”.
Douglas et al., Int. J. Obes. vol. 7 (1983), pp. 591-595, “Plasma phentermine levels, weight loss and side-effects”.
Ford et al., JAMA, vol. 287(3) (2002), pp. 356-359, “Prevalence of the metabolic syndrome among US adults”.
Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, Jun. 14-19, 1997, Nashville, TN.
Bakshi Raman K.
Guo Liangqin
Hong Qingmei
Nargund Ravi P.
Pollard Patrick G.
Brown Baerbel R.
Freistein Andrew B.
Merck & Co. , Inc.
Shameem Golam M. M.
Winokur Melvin
LandOfFree
Acylated piperazine derivatives as melanocortin-4 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylated piperazine derivatives as melanocortin-4 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylated piperazine derivatives as melanocortin-4 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3791972